How many units is 1.7 mg of semaglutide depends on your vial's concentration. At the most common 5 mg/ml concentration, 1.7 mg of semaglutide equals 34 units on a U100 insulin syringe. If your vial is 2.5 mg/ml, 1.7 mg equals 68 units. At 10 mg/ml, 1.7 mg equals 17 units. The 1.7 mg dose is the fourth titration step in the FDA-approved Wegovy schedule, typically used during weeks 13 to 16 of therapy.

Checkout this GLP-1 dose calculator for accurate insights.

Quick Answer Table: 1.7 mg Semaglutide to Units

The 1.7 mg dose is the fourth titration step in the FDA-approved Wegovy schedule, transitioning patients toward the 2.4 mg maintenance dose.

Concentration

Volume Needed

Units on U100 Syringe

2.5 mg/ml

0.68 ml

68 units

5 mg/ml (most common)

0.34 ml

34 units

10 mg/ml

0.17 ml

17 units

Here is what to know up front about 1.7 mg semaglutide units. This is the fourth titration step in the FDA-approved Wegovy schedule, used during weeks 13 to 16 before reaching the 2.4 mg maintenance dose, per the FDA Wegovy prescribing information. The 1.7 mg dose was added in 2022 as an intermediate step between 1 mg and 2.4 mg to improve tolerability. At the most common 5 mg/ml concentration, this dose equals 34 units on a U100 insulin syringe. For broader context, see compounded semaglutide dosage chart.

The Math: How We Calculated This

The formula for compounded semaglutide 1.7mg to units is:

Units = (mg dose ÷ concentration in mg/ml) × 100

Worked example at 5 mg/ml (most common):

1.7 mg ÷ 5 mg/ml = 0.34 ml 0.34 ml × 100 = 34 units on a U100 insulin syringe

At 2.5 mg/ml: 1.7 ÷ 2.5 = 0.68 ml = 68 units

At 10 mg/ml: 1.7 ÷ 10 = 0.17 ml = 17 units

The 1.7mg to units conversion gives whole numbers at all three concentrations, making this dose easier to draw than some other titration steps.

Why 1.7 mg Is in the Wegovy Schedule

The 1.7 mg dose was added to the Wegovy titration schedule to improve patient tolerability. Originally, the schedule jumped directly from 1 mg to 2.4 mg, which caused significant GI side effects for many patients. The 1.7 mg intermediate step helps the body adjust to higher doses more gradually.

The semaglutide 1.7 mg dose:

  • Is the fourth FDA-approved titration step (after 0.25, 0.5, and 1 mg)

  • Transitions patients from 1 mg toward the 2.4 mg maintenance dose

  • Provides strong therapeutic effects in clinical trials

  • Is used during weeks 13 to 16 of the Wegovy schedule

  • Reduces GI side effects compared to jumping directly from 1 mg to 2.4 mg

Some patients respond well at 1.7 mg and stay at this dose long-term if they reach their weight loss goals. Others continue to 2.4 mg for stronger effects.

How to Draw 1.7 mg Semaglutide

The semaglutide 1.7 mg syringe choice depends on concentration.

At 5 mg/ml (34 units): Use a 0.5 ml insulin syringe. The 34 unit mark sits in the upper two-thirds of the barrel. A 1 ml syringe also works but with less precision.

At 2.5 mg/ml (68 units): Use a 1 ml insulin syringe. The 68 unit mark is near the top of the barrel.

At 10 mg/ml (17 units): Use a 0.3 ml insulin syringe. The 17 unit mark is in the middle of the barrel.

For full guidance on syringe sizes, see how to read insulin syringe units.

Common Mistakes With 1.7 mg Conversion

Drawing 17 units when you need 34 units. At 5 mg/ml, the 1.7 mg dose is 34 units. Drawing only 17 units would deliver 0.85 mg, half the intended dose. The 1.7 mg dose is meant to be a transition step toward 2.4 mg, and the proper unit count matters.

Skipping from 1 mg to 2.4 mg. Some patients try to skip the 1.7 mg step. The titration schedule was intentionally updated to include 1.7 mg to reduce GI side effects when transitioning to the maintenance dose. Skipping can cause severe nausea and vomiting.

Confusing 1.7 mg with 17 mg. A 17 mg dose would be 10x the 1.7 mg dose and far above any approved semaglutide dose. The decimal point is critical at this dose level.

Continuing 1.7 mg as long-term maintenance. For Wegovy patients, 1.7 mg is a transition step. The maximum approved Wegovy dose is 2.4 mg. Some patients stay at 1.7 mg if they reach their goals, but this should be discussed with your physician.

Frequently Asked Questions

The ml depends on concentration. At 2.5 mg/ml, 1.7 mg = 0.68 ml. At 5 mg/ml (most common), 1.7 mg = 0.34 ml. At 10 mg/ml, 1.7 mg = 0.17 ml. The mg dose stays the same; only the volume changes.

Yes. The 1.7 mg dose is the fourth titration step in the FDA-approved Wegovy schedule (weeks 13 to 16). It was added to the schedule to improve tolerability when transitioning from 1 mg to the 2.4 mg maintenance dose. The 1.7 mg dose is not used for Ozempic (type 2 diabetes), which max at 2 mg.

Most US compounding pharmacies use 5 mg/ml as of 2026, where 1.7 mg = 34 units on a U100 syringe. Other common concentrations include 2.5 mg/ml (68 units) and 10 mg/ml (17 units). Verify your specific vial label.

Yes, depending on concentration. At 5 mg/ml (34 units), a 0.5 ml syringe with 1-unit markings works well. At 2.5 mg/ml (68 units), a 1 ml syringe is needed since 68 units exceeds the 50 unit capacity of a 0.5 ml syringe. At 10 mg/ml (17 units), a 0.3 ml or 0.5 ml syringe is ideal.

The FDA-approved Wegovy schedule recommends 4 weeks at 1.7 mg before moving to 2.4 mg. Some patients with significant GI side effects stay at 1.7 mg longer before progressing. Some patients who reach weight loss goals at 1.7 mg may stay long-term. Always follow your physician's titration plan.

The 1.7 mg dose provides meaningful weight loss in clinical trials, but the strongest results come with the 2.4 mg maintenance dose. Some patients achieve their goals at 1.7 mg. Others need the higher 2.4 mg dose for full benefit. Talk with your physician about your specific goals.